Loading clinical trials...

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (The Z-AMD Study): A Randomized Controlled Pilot Study

NCT04304755•Oslo University Hospital

View on ClinicalTrials.gov

Summary

A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).

Detailed Description

This is a one-year, randomized, controlled pilot study. A total of 40 treatment-naïve nAMD patients will be allocated 1:1 to receive an intravenous infusion of either zoledronic acid (ZA) 5 mg or placebo at baseline and after 26 weeks as adjuvant therapy to intravitreal anti-VEGF injections in accordance with a treat and extend algorithm; bevacizumab is the first-line treatment, and refractory eyes are converted to aflibercept. The participants will be recruited among patients admitted to the Department of Ophthalmology at Oslo University Hospital (OUH). The department is the largest provider of retinal care in Norway and serves a local community of almost one million people, which makes it well-suited for recruitment. Administration of ZA or placebo will take place at Pilestredet Park Specialist Centre, an endocrinology clinic in Oslo with particular interest in treatment of osteoporosis. The Clinical Trial Unit at OUH will monitor the study.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Active, treatment-naïve neovascular AMD in the study eye, intraretinal or subretinal fluid involving the fovea centre on optical coherence tomography (OCT), and evidence of choroidal neovascularization on fluorescein angiography (FA) and/or OCT angiography (OCT-A).
•2. Age ≥50 years
•3. Best-corrected visual acuity (BCVA) between 0.1 and 1.0 logMAR
•4. Menopausal for at least one year
•5. Only one eye per patient will be recruited for the study. If both eyes are eligible for the study, the eye with the wors best-corrected Visual acuity (BCVA) will be selected as the study eye.
•6. Subjects must give written informed consent before any study related procedures are performed

Exclusion Criteria

•1. Lesions comprising more than 50% blood or fibrosis involving the fovea centre
•2. Polypoidal choroidal vasculopathy (PCV) - indocyanine green (ICG) angiography is performed at the discretion of the investigator on clinical suspicion of PCV
•3. Presence of other ocular disease causing concurrent vision loss
•4. Presence of ocular disease making intravitreal treatment contraindicated (e.g. current ocular or periocular infection, active uveitis or uncontrolled glaucoma/intraocular pressure ≥ 25 mmHg)
•5. Systemic anti-vascular endothelial growth factor (anti-VEGF) or bisphosphonate treatment within one year preceding the initial study treatment
•6. Confirmed or suspected active malignancy
•7. Other factors (i.e. lack of cooperation) that, in the opinion of the investigator, can interfere with the study protocol
•8. Known or suspected hypersensitivity to any of the trial products
•9. Hypocalcemia (total Ca \< 2.15 mmol/L)
•10. Renal impairment (estimated ClCR \< 35 ml/min).

Locations (2)

Spesialistsenteret Pilestredet Park

Oslo, Norway

Oslo university hospital, Department of Ophthamology

Oslo, Norway

Key Dates

Start Date

October 25, 2021

Primary Completion Date

January 24, 2024

Completion Date

January 24, 2024

Last Updated

April 5, 2024

Enrollment

ACTUAL participants

Conditions

Neovascular Age-related Macular Degeneration

Interventions

Zoledronic Acid 5 MG in 5 ML Injection

DRUG

Placebos

DRUG

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

NCT05562947

Neovascular Age-related Macular DegenerationnAMD

View study

RECRUITINGPHASE3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

NCT05904028

Neovascular Age-related Macular Degeneration

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 5, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

Inclusion Criteria

Exclusion Criteria

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Gene Therapy(FT-003) for Wet AMD

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products